Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.22.0.1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 20, 2021
USD ($)
Oct. 21, 2020
USD ($)
Sep. 30, 2015
USD ($)
item
Sep. 30, 2015
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers         $ 36,518 $ 27,941    
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation   $ 7,300            
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period     180 days          
Number of performance obligations | item     1          
Cash payment received   17,700           $ 37,000
Revenue from contracts with customers $ 35,000 $ 25,000     35,000 25,000 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 410,000   $ 480,000 $ 480,000        
Royalty payment period       10 years        
Contract assets         0 0    
Contract liabilities         0 0    
Capitalized contract costs         $ 0 $ 0